How Fosamax Triggers Osteonecrosis of the Jaw: Pathophysiology and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specialized Risk: The Legacy of Oral Health Education

The legacy of general health and science information has long served as a foundation for public understanding of physiological processes and disease prevention. Within this framework, the oral cavity has been contextualized primarily through the lens of hygiene, infection, and systemic health markers. This broad perspective has historically emphasized the mouth as a window to overall well-being, focusing on conditions such as caries, periodontal disease, and salivary gland disorders. However, as clinical knowledge advances, the scope of oral health concerns has expanded beyond these traditional boundaries to include iatrogenic and environmental influences. In particular, the transition from a general health context to a more specialized occupational exposure concern arises when considering the impact of pharmaceutical agents on oral tissues. The shift in focus becomes necessary when evaluating how certain medications, originally developed for systemic conditions, may inadvertently affect the jawbone and surrounding structures. This pivot requires a careful re-examination of the mouth not merely as a site of common ailments but as a potential target for drug-related complications. The emerging discourse now integrates the legacy of general health education with a nuanced appreciation for how therapeutic exposures can alter oral pathophysiology, thereby bridging the gap between broad health literacy and specific risk assessment in clinical and occupational settings.

Bridging to Fosamax: A Medication with Oral Implications

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption by osteoclasts, thereby increasing bone mass and reducing fracture risk. However, a serious adverse effect associated with Fosamax use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The pathophysiology linking Fosamax to ONJ involves several mechanistic pathways. Bisphosphonates, including Fosamax, accumulate in bone tissue and suppress osteoclast activity. In the jawbone, which has a high turnover rate due to constant mechanical stress from chewing and the presence of teeth, this suppression can lead to impaired bone remodeling. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that helps understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This research indicates that bisphosphonate treatment affects the mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These changes can compromise the jawbone's ability to heal after minor trauma, such as tooth extraction, or in the presence of local infection.

Clinical Evidence and Risk Factors for Fosamax-Associated ONJ

ONJ associated with Fosamax can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The clinical presentation of ONJ typically involves exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is based on clinical examination and imaging, with exclusion of metastatic disease. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation and Management Considerations

Regarding causation considerations for affected patients, the relationship between Fosamax use and ONJ is well-documented in the medical literature. The FDA-approved labeling for Fosamax includes a warning about ONJ, stating that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is reflected in the labeling, which identifies known risk factors and recommends clinical management strategies. However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The timeline between exposure to Fosamax and documented harm from ONJ can vary widely. Symptoms may appear as early as one day after starting the drug or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, management includes discontinuation of Fosamax if severe symptoms develop, along with appropriate dental care and treatment of infection. In summary, Fosamax can trigger ONJ through its suppression of bone remodeling in the jawbone, particularly in the presence of risk factors such as dental procedures or infection. The evidence supports a causal link between Fosamax use and ONJ, with labeling that provides warnings and guidance for risk mitigation. Patients and healthcare providers should be aware of the potential for ONJ, especially with prolonged use and in the context of invasive dental treatments.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) suppresses osteoclast activity, leading to impaired bone remodeling in the jawbone. This is particularly problematic because the jawbone has a high turnover rate due to mechanical stress from chewing and the presence of teeth. The suppression of bone remodeling compromises the jawbone's ability to heal after minor trauma, such as tooth extraction, or in the presence of local infection, ultimately leading to osteonecrosis (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How soon after starting Fosamax can ONJ symptoms appear?

The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.